Passing of Australia's PBS Amendment Bill welcomed by trade group

13 February 2018

Trade group Medicines Australia welcomes the passing of the PBS National Health Amendment (Pharmaceutical Benefits - Budget and Other Measures) Bill 2017.

This Bill amends the National Health Act to implement measures negotiated with Medicines Australia on behalf of the innovative pharmaceutical industry and announced in the 2017 Budget.

Medicines Australia chief executive Milton Catelin said: “This Bill, and the Strategic Agreement that underpins it, represents two years of consultation with industry, government and the wider sector to ensure that cost savings are delivered by industry, into the PBS”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK